TY  - JOUR
AU  - Ko, Andrew H
AU  - Kim, Kyu-Pyo
AU  - Siveke, Jens
AU  - Lopez, Charles D
AU  - Lacy, Jill
AU  - O'Reilly, Eileen M
AU  - Macarulla, Teresa
AU  - Manji, Gulam A
AU  - Lee, Jeeyun
AU  - Ajani, Jaffer
AU  - Alsina Maqueda, Maria
AU  - Rha, Sun-Young
AU  - Lau, Janet
AU  - Al-Sakaff, Nedal
AU  - Allen, Simon
AU  - Lu, Danny
AU  - Shemesh, Colby S
AU  - Gan, Xinxin
AU  - Cha, Edward
AU  - Oh, Do-Youn
TI  - Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
JO  - The oncologist
VL  - 28
IS  - 6
SN  - 1083-7159
CY  - Oxford
PB  - Oxford University Press
M1  - DKFZ-2023-00568
SP  - 553-e472
PY  - 2023
N1  - 2023 Jun 2;28(6):553-e472
AB  - The MORPHEUS platform comprises multiple open-label, randomized, phase Ib/II trials designed to identify early efficacy and safety signals of treatment combinations across cancers. Atezolizumab (anti-programmed cell death 1 ligand 1 [PD-L1]) was evaluated in combination with PEGylated recombinant human hyaluronidase (PEGPH20).In 2 randomized MORPHEUS trials, eligible patients with advanced, previously treated pancreatic ductal adenocarcinoma (PDAC) or gastric cancer (GC) received atezolizumab plus PEGPH20, or control treatment (mFOLFOX6 or gemcitabine plus nab-paclitaxel [MORPHEUS-PDAC]; ramucirumab plus paclitaxel [MORPHEUS-GC]). Primary endpoints were objective response rates (ORR) per RECIST 1.1 and safety.In MORPHEUS-PDAC, ORRs with atezolizumab plus PEGPH20 (n = 66) were 6.1
KW  - PD-L1 (Other)
KW  - basket study (Other)
KW  - combination therapy (Other)
KW  - gastric cancer (Other)
KW  - hyaluronan (Other)
KW  - immunotherapy (Other)
KW  - pancreatic cancer (Other)
KW  - proof of concept (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36940261
DO  - DOI:10.1093/oncolo/oyad022
UR  - https://inrepo02.dkfz.de/record/274366
ER  -